BTIG raised the firm’s price target on AtriCure (ATRC) to $58 from $57 and keeps a Buy rating on the shares after the company’s Investor Day. The firm sees the company’s new products and expansion to power low-teens sales CAGR and greater profitability into 2028, with acceleration in growth rates beyond, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC: